Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.

Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study

Open access

Abstract

Psychotic illnesses show variable responses to treatment. Determining the neurobiology underlying this is important for precision medicine and the development of better treatments. It has been proposed that dopaminergic differences underlie variation in response, with striatal dopamine synthesis capacity (DSC) elevated in responders and unaltered in non-responders. We therefore aimed to test this in a prospective cohort, with a nested case-control comparison. 40 volunteers (26 patients with first-episode psychosis and 14 controls) received an 18 F-DOPA Positron Emission Tomography scan to measure DSC (Ki cer ) prior to antipsychotic treatment. Clinical assessments (Positive and Negative Syndrome Scale, PANSS, and Global Assessment of Functioning, GAF) occurred at baseline and following antipsychotic treatment for a minimum of 4 weeks. Response was defined using improvement in PANSS Total score of >50%. Patients were followed up for at least 6 months, and remission criteria applied. There was a significant effect of group on Ki cer in associative striatum (F (2, 37) = 7.9, p = 0.001). Ki cer was significantly higher in responders compared with non-responders (Cohen’s d = 1.55, p = 0.01) and controls (Cohen’s d = 1.31, p = 0.02). Ki cer showed significant positive correlations with improvements in PANSS-positive ( r = 0.64, p < 0.01), PANSS negative (rho = 0.51, p = 0.01), and PANSS total (rho = 0.63, p < 0.01) ratings and a negative relationship with change in GAF ( r = −0.55, p < 0.01). Clinical response is related to baseline striatal dopaminergic function. Differences in dopaminergic function between responders and non-responders are present at first episode of psychosis, consistent with dopaminergic and non-dopaminergic sub-types in psychosis, and potentially indicating a neurochemical basis to stratify psychosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-018-0042-4

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean dopamine synthesis capacity by group. Dopamine synthesis capacity is elevated at baseline in patients who subsequently respond to antipsychotic treatment, compared to controls and non-responders (Cohen’s d effect size = 1.31 and 1.55, respectively). Error bars indicate standard error of the mean
Fig. 1 Mean dopamine synthesis capacity by group. Dopamine synthesis capacity is elevated at baseline in patients who subsequently respond to antipsychotic treatment, compared to controls and non-responders (Cohen’s d effect size = 1.31 and 1.55, respectively). Error bars indicate standard error of the meanCC BY · PubMed Central
Fig. 2 Voxel-wise analysis of treatment responders compared to non-responders. Increased dopamine synthesis capacity, relative to non-responder patients (N = 13), in patients who respond to treatment (N = 13). The most significant increase was in voxels in right caudate (Peak MNI coordinates x = 18, y = 20, z = 2; pFWE corr = 0.026) and left putamen (Peak MNI coordinates x = −24, y = 8, z = −2; pFWE corr = 0.027)
Fig. 2 Voxel-wise analysis of treatment responders compared to non-responders. Increased dopamine synthesis capacity, relative to non-responder patients (N = 13), in patients who respond to treatment (N = 13). The most significant increase was in voxels in right caudate (Peak MNI coordinates x = 18, y = 20, z = 2; pFWE corr = 0.026) and left putamen (Peak MNI coordinates x = −24, y = 8, z = −2; pFWE corr = 0.027)CC BY · PubMed Central
Fig. 3 Voxel-wise analysis of treatment responders compared to controls. Increased dopamine synthesis capacity, relative to controls (N = 14), in patients who respond to treatment (N = 13). The most significant increase was in a voxel in both left (Peak MNI coordinates x = −12, y = 16, z = 6; pFWE corr < 0.001) and right caudate (Peak MNI coordinates x = 14, y = 18, z = 0; pFWE corr < 0.001)
Fig. 3 Voxel-wise analysis of treatment responders compared to controls. Increased dopamine synthesis capacity, relative to controls (N = 14), in patients who respond to treatment (N = 13). The most significant increase was in a voxel in both left (Peak MNI coordinates x = −12, y = 16, z = 6; pFWE corr < 0.001) and right caudate (Peak MNI coordinates x = 14, y = 18, z = 0; pFWE corr < 0.001)CC BY · PubMed Central
Fig. 4 Relationship between baseline dopamine synthesis capacity and subsequent antipsychotic response. A positive association was found between associative striatum dopamine synthesis capacity and subsequent improvement in positive psychotic symptoms, measured using the PANSS-positive subscale
Fig. 4 Relationship between baseline dopamine synthesis capacity and subsequent antipsychotic response. A positive association was found between associative striatum dopamine synthesis capacity and subsequent improvement in positive psychotic symptoms, measured using the PANSS-positive subscaleCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 2

  1. Taylor D, Paton C, Kapur S, (eds). The Maudsley Prescribing Guidelines in Psychiatry. 11th Edition. West Sussex: Wiley-Blackwell: Chichester; 2012.
  2. Busner J, Targum SD. The clinical global impressions scale. Psychiatry. 2007;4:28–37.

Cited by

See all 187

Metadata

Authors
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Turkheimer, F. E., Stone, J., Egerton, A., McGuire, P., Kapur, S., & Howes, O. D.
Affiliations
King's College London (GB)
Corresponding author
Howes, Oliver D
Venue
Molecular Psychiatry
Published
2018-04-20
Volume
24
Issue
10
Pages
1502-1512
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2799407405
Cited by
183
References
68
Citations by year
2026: 12 · 2025: 22 · 2024: 24 · 2023: 13 · 2022: 29 · 2021: 37 · 2020: 16 · 2019: 24 · 2018: 6
FWCI
16.33
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Wellcome Trust (094849, 094849/Z/10/Z)
  • Maudsley Charity
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Institute for Health and Care Research (ACF-2016-17-005)
  • King's College London
  • Servier
  • H. Lundbeck A/S
  • Medical Research Council (MC- A656-5QD30, MR/N026063/1)
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
first-episode psychosis, treatment response, antipsychotic treatment response, 18F-DOPA PET, dopaminergic activity, striatum, positive and negative symptoms, functional outcome, precision medicine
MeSH terms
Adult, Corpus Striatum, Dihydroxyphenylalanine, Dopamine, Female, Humans, Male, Prospective Studies, Psychiatric Status Rating Scales, Psychotic Disorders, Antipsychotic Agents, Cohort Studies, Case-Control Studies, Treatment Outcome, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. https://app.cochat.ai/papers/10.1038/s41380-018-0042-4
The paper
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Turkheimer, F. E., Stone, J., Egerton, A., McGuire, P., Kapur, S., & Howes, O. D. (2019). Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0042-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.